TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858

1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause of occurrence: TFDA has approved to proceed Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858. 6.Countermeasures: None 7.Any other matters […]